ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 0632

Cutaneous Lupus Erythema and Scale Have Similar Six-month Trends Without Significant Impact from Race/ethnicity or Disease Subtype

Tyler Cepica1, Lillian Xie2, Daniella Faden2, Caroline Stone3, Victoria Werth4 and Benjamin Chong5, 1University of Texas Southwestern Medical School, Benbrook, TX, 2University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania, Phiiladelphia, PA, 4Hospital of the University of Pennsylvania, Philadelphia, PA, 5The University of Texas Southwestern Medical Center, Department of Dermatology, Dallas, TX

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: Autoinflammatory diseases, Cutaneous, Dermatology, Outcome measures, Systemic lupus erythematosus (SLE)

Session Information

Date: Saturday, November 16, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated outcome measure designed to assess cutaneous lupus erythematosus (CLE) activity (CLASI-A) and damage (CLASI-D). Scoring is separated by anatomic site, with greater weight assigned to the head and neck. CLASI-A specifically assesses erythema, scale, alopecia, and mucous membrane involvement, with maximum scores of 39, 26, 4, and 1, respectively. There is little data depicting how CLASI-A erythema and scale scores change over time in relation to total CLASI-A scores. Thus, we designed a prospective observational CLE patient cohort study that further elucidates trends in erythema and scale to better understand disease course. Overall, we hypothesize that CLASI-A erythema and scale scores trend closely and contribute similar changes in total CLASI-A.

Methods: 130 CLE patients on standard-of-care therapies were followed at regular two-month intervals over 6 months. Patients were recruited from three outpatient dermatology clinics from July 2018 to May 2023. CLE disease activity was assessed using the Cutaneous Lupus Disease Area and Severity Index (CLASI). The primary and secondary outcomes were the mean change and mean percent change (MPC) of total CLASI-A, CLASI-A erythema, and CLASI-A scale scores between baseline and each follow-up visit. Predictive variables associated with disease activity trends were analyzed with linear mixed-effects modeling adjusted for baseline CLASI scores, time, and within-subject correlation.

Results: The mean changes in CLASI-A scores over six months were -4.3±8.6 for total CLASI-A, -2.7±5.9 for CLASI-A erythema, and -1.1±2.9 for CLASI-A scale. The MPCs in total CLASI-A, CLASI-A erythema, and CLASI-A scale were -19.8%±72.0%, -20.4%±63.9%, and -16.4%±71.0%, respectively (Figure 1). No significant differences existed between the MPC of CLASI-A erythema and scale (p=0.651). Mean changes of CLASI-A erythema and scale at visit 4 were -3.1±5.6 and -1.2±3.1 for White Non-Hispanic patients (n=39), -2.9±6.0 (p=0.211) and -1.3±3.0 (p=0.066) for Black patients (n=68), -1.5±3.0 and -0.4±1.1 for localized discoid lupus erythematosus (DLE) (n=34), -2.2±6.9 (p=0.136) and -1.2±3.6 (p=0.231) for generalized DLE (n=56), and -5.4±6.1 (p=0.603)  and -2.2±2.9 (p=0.693) for subacute CLE (n=31), respectively (Tables 1-2).

Conclusion: CLASI-A erythema and scale trend similarly over 6 months and are well represented by changes in total CLASI-A, highlighting CLASI-A’s reliability. Furthermore, erythema and scale trends were not impacted by either race and ethnicity or CLE subtype, emphasizing the CLASI’s sensitivity to capture changes in activity across varying skin pigmentations and CLE subtypes and further underscoring its utility for use in clinical trials.

Supporting image 1

Mean change (A) and mean percent change (B) in total CLASI-A, CLASI-A erythema, and CLASI-A scale scores over 6 months.

Supporting image 2

Association of race/ethnicity and predominant CLE subtype with CLASI-A erythema progression over time

Supporting image 3

Association of race/ethnicity and predominant CLE subtype with CLASI-A scale progression over time


Disclosures: T. Cepica: None; L. Xie: None; D. Faden: None; C. Stone: None; V. Werth: AbbVie, 2, 5, Amgen, 2, 5, Argenx, 2, 5, AstraZeneca, 2, 5, Beacon Bioscience, 2, 5, Biogen, 2, 5, Bristol Myers Squibb, 2, 5, Corcept Therapeutics, 2, 5, Crisalis, 2, 5, CSL Behring, 2, 5, Cugene, 2, 5, EMD Serono, 2, 5, Genentech, 2, 5, Gilead, 2, 5, GSK, 2, 5, Idera Pharmaceuticals, 2, 5, Incyte, 2, 5, Janssen, 2, 5, Kyowa Kirin, 2, 5, Lilly, 2, 5, Lupus Research Alliance, 2, 5, Medimmune, 2, 5, Medscape, 2, 5, Nektar, 2, 5, Principia Biopharma, 2, 5, Resolve Biosciences, 2, 5, UCB, 2, 5, Viela Bio, 2, 5; B. Chong: Amgen, 2, Biogen Inc, 2, Bristol-Myers Squibb(BMS), 2, Daavlin Corp, 5, Lupus Research Alliance, 2, MAPI Research Trust, 9, Merck/MSD, 2.

To cite this abstract in AMA style:

Cepica T, Xie L, Faden D, Stone C, Werth V, Chong B. Cutaneous Lupus Erythema and Scale Have Similar Six-month Trends Without Significant Impact from Race/ethnicity or Disease Subtype [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/cutaneous-lupus-erythema-and-scale-have-similar-six-month-trends-without-significant-impact-from-race-ethnicity-or-disease-subtype/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cutaneous-lupus-erythema-and-scale-have-similar-six-month-trends-without-significant-impact-from-race-ethnicity-or-disease-subtype/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology